<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419820</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TMG-102</org_study_id>
    <nct_id>NCT02419820</nct_id>
  </id_info>
  <brief_title>Dose-escalation, Repeated and Single Oral Dosing Study</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered With Aspirin and Clopidogrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral&#xD;
      Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of APD791&#xD;
      (Temanogrel) Co-administered with Aspirin and Clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To investigate pharmacokinetic and pharmacodynamic characteristics of Temanogrel when&#xD;
           orally co-administered with Aspirin and/or Clopidogrel in healthy subject. a person&#xD;
           determined to be suitable for the purpose of this clinical trial by investigator with&#xD;
           consideration for the age and the health status of a volunteer is selected&#xD;
&#xD;
        2. Assess the safety of Temanogrel when orally co-administered with Aspirin and/or&#xD;
           Clopidogrel in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor Decision&#xD;
  </why_stopped>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Day1, Day2, Day3, Day4, Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Day1, Day2, Day3, Day4, Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics-% inhibition of serotonin-stimulated platelet aggregation</measure>
    <time_frame>Day1, Day2, Day4, Day7, Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics-change of serotonin-stimulated platelet aggregation</measure>
    <time_frame>Day1, Day4, Day7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics-% inhibition of TRAP-induced platelet aggregation</measure>
    <time_frame>Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse event monitoring</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical examination</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory test</measure>
    <time_frame>up to post-study visit(8day±2)</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>APD791 10mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 10mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 20mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 20mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 40mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 40mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 10mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 20mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 40mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 80mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 160mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 240mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 320mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 320mg single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>APD791 placebo for single dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 2mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 2mg multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 5mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 5mg multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 10mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 10mg multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 20mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 placebo for multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>APD791 placebo for multiple dose + Aspirin + Clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD791</intervention_name>
    <description>Temanogrel</description>
    <arm_group_label>APD791 10mg</arm_group_label>
    <arm_group_label>APD791 10mg MD</arm_group_label>
    <arm_group_label>APD791 10mg single dose</arm_group_label>
    <arm_group_label>APD791 160mg</arm_group_label>
    <arm_group_label>APD791 20mg</arm_group_label>
    <arm_group_label>APD791 20mg MD</arm_group_label>
    <arm_group_label>APD791 20mg single dose</arm_group_label>
    <arm_group_label>APD791 240mg</arm_group_label>
    <arm_group_label>APD791 2mg MD</arm_group_label>
    <arm_group_label>APD791 320mg</arm_group_label>
    <arm_group_label>APD791 40mg</arm_group_label>
    <arm_group_label>APD791 40mg single dose</arm_group_label>
    <arm_group_label>APD791 5mg MD</arm_group_label>
    <arm_group_label>APD791 80mg</arm_group_label>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <other_name>Temanogrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel</description>
    <arm_group_label>APD791 10mg</arm_group_label>
    <arm_group_label>APD791 10mg MD</arm_group_label>
    <arm_group_label>APD791 160mg</arm_group_label>
    <arm_group_label>APD791 20mg</arm_group_label>
    <arm_group_label>APD791 20mg MD</arm_group_label>
    <arm_group_label>APD791 240mg</arm_group_label>
    <arm_group_label>APD791 2mg MD</arm_group_label>
    <arm_group_label>APD791 320mg</arm_group_label>
    <arm_group_label>APD791 40mg</arm_group_label>
    <arm_group_label>APD791 5mg MD</arm_group_label>
    <arm_group_label>APD791 80mg</arm_group_label>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin</description>
    <arm_group_label>APD791 10mg</arm_group_label>
    <arm_group_label>APD791 10mg MD</arm_group_label>
    <arm_group_label>APD791 160mg</arm_group_label>
    <arm_group_label>APD791 20mg</arm_group_label>
    <arm_group_label>APD791 20mg MD</arm_group_label>
    <arm_group_label>APD791 240mg</arm_group_label>
    <arm_group_label>APD791 2mg MD</arm_group_label>
    <arm_group_label>APD791 320mg</arm_group_label>
    <arm_group_label>APD791 40mg</arm_group_label>
    <arm_group_label>APD791 5mg MD</arm_group_label>
    <arm_group_label>APD791 80mg</arm_group_label>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <other_name>Aspirin Protect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for APD791</intervention_name>
    <description>Placebo for APD791</description>
    <arm_group_label>APD791 Placebo</arm_group_label>
    <arm_group_label>APD791 placebo MD</arm_group_label>
    <other_name>Placebo for Temanogrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. a healthy adult between 20 and 45 years old at the time of visit for screening&#xD;
&#xD;
          2. a person who is able to give written consent&#xD;
&#xD;
          3. a person between 50 and 85 kg at the time of visit for screening&#xD;
&#xD;
          4. a woman who is negative on a serum hCG test at the time of visit and the day before a&#xD;
             trial, and who is not nursing, a woman who agrees on double contraception, medically&#xD;
             approved, from the time of visit for screening to 90 days after the last&#xD;
             administration of a clinical trial drug, or who had a contraceptive operation no later&#xD;
             than 120 days before visit for screening, or who is menopausal, a man who had a&#xD;
             contraceptive operation no later than 120 days before visit for screening, or who&#xD;
             agrees on double contraception, medically approved, from the time of visit for&#xD;
             screening to 90 days after the last administration of a clinical trial drug, and also&#xD;
             agree not to donate sperm&#xD;
&#xD;
          5. a person more than hemoglobin 12 g/dL at the time of screening (a woman more than&#xD;
             hemoglobin 11 g/dL)&#xD;
&#xD;
          6. a person whose vital signs were in the normal range at the time of visit for&#xD;
             screening, or who is medically determined not to be clinically significant by an&#xD;
             investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer&#xD;
             within 90 days from the time of visit for screening&#xD;
&#xD;
          2. a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease,&#xD;
             ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or&#xD;
             herniotomy) affecting the absorption of a clinical trial drug&#xD;
&#xD;
          3. a person with the medical history of blood coagulation disorder or hemorrhagic&#xD;
             diseases, or with clinically significant abnormal findings decided by a investigator&#xD;
             on blood coagulation test at the time of screening&#xD;
&#xD;
          4. a woman with the medical history of dysfunctional uterine bleeding within a year from&#xD;
             the time of visit for screening&#xD;
&#xD;
          5. a person with the medical history of epilepsy or convulsion&#xD;
&#xD;
          6. a person with the medical history of internal organ transplant&#xD;
&#xD;
          7. a person expected to be hard to complete a clinical trial because of surgery or&#xD;
             medical procedures planned within a clinical trial period&#xD;
&#xD;
          8. a person with the medical history of clinically significant new diseases within 30&#xD;
             days from the time of visit for screening according to investigator's decision&#xD;
&#xD;
          9. a person with hypersensitivity reaction to a drug or gelatin, or the medical history&#xD;
             of clinically significant hypersensitivity reaction&#xD;
&#xD;
         10. a person with the history of drug abuse, or with a positive reaction to a drug&#xD;
             possible to be abused on urine drug screening&#xD;
&#xD;
         11. a person with the medical history of alcohol abuse within two years from the time of&#xD;
             visit for screening&#xD;
&#xD;
         12. a person who is a smoker, or with a positive reaction on a urine nicotine test&#xD;
             conducted at the time of visit for screening&#xD;
&#xD;
         13. a person who donated whole blood within 60 days or constituents of blood within 30&#xD;
             days, or received a blood transfusion within 30 days from the time of visit for&#xD;
             screening&#xD;
&#xD;
         14. a person taking other clinical trial drugs within 90 days from the time of visit for&#xD;
             screening&#xD;
&#xD;
         15. a person taking a prescription drug within 30 days, or a contraindicated drug or&#xD;
             oriental medicine within 14 days from the time of visit for screening&#xD;
&#xD;
         16. a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test,&#xD;
             HIV test, syphilis test)&#xD;
&#xD;
         17. a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper&#xD;
             limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or&#xD;
             creatinine more than 1.25 times of the reference upper limit(UNL)&#xD;
&#xD;
         18. a person expected to be hard to complete a clinical trial due to physical or mental&#xD;
             status according to investigator's medical decision at the time of visit for screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gyunseop Bae, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>APD791</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

